297 related articles for article (PubMed ID: 14760123)
1. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis.
Mangel J; Leitch HA; Connors JM; Buckstein R; Imrie K; Spaner D; Crump M; Pennell N; Boudreau A; Berinstein NL
Ann Oncol; 2004 Feb; 15(2):283-90. PubMed ID: 14760123
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
3. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study.
Brugger W; Hirsch J; Grünebach F; Repp R; Brossart P; Vogel W; Kopp HG; Manz MG; Bitzer M; Schlimok G; Kaufmann M; Ganser A; Fehnle K; Gramatzki M; Kanz L
Ann Oncol; 2004 Nov; 15(11):1691-8. PubMed ID: 15520073
[TBL] [Abstract][Full Text] [Related]
4. Integrating monoclonal antibodies into the management of mantle cell lymphoma.
Berinstein NL; Mangel J
Semin Oncol; 2004 Feb; 31(1 Suppl 2):2-6. PubMed ID: 15042527
[TBL] [Abstract][Full Text] [Related]
5. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
Damon LE; Johnson JL; Niedzwiecki D; Cheson BD; Hurd DD; Bartlett NL; Lacasce AS; Blum KA; Byrd JC; Kelly M; Stock W; Linker CA; Canellos GP
J Clin Oncol; 2009 Dec; 27(36):6101-8. PubMed ID: 19917845
[TBL] [Abstract][Full Text] [Related]
6. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
7. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome.
Dreger P; Rieger M; Seyfarth B; Hensel M; Kneba M; Ho AD; Schmitz N; Pott C
Haematologica; 2007 Jan; 92(1):42-9. PubMed ID: 17229634
[TBL] [Abstract][Full Text] [Related]
8. Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma.
Till BG; Gooley TA; Crawford N; Gopal AK; Maloney DG; Petersdorf SH; Pagel JM; Holmberg L; Bensinger W; Press OW
Leuk Lymphoma; 2008 Jun; 49(6):1062-73. PubMed ID: 18452065
[TBL] [Abstract][Full Text] [Related]
9. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).
Gianni AM; Magni M; Martelli M; Di Nicola M; Carlo-Stella C; Pilotti S; Rambaldi A; Cortelazzo S; Patti C; Parvis G; Benedetti F; Capria S; Corradini P; Tarella C; Barbui T
Blood; 2003 Jul; 102(2):749-55. PubMed ID: 12663455
[TBL] [Abstract][Full Text] [Related]
10. Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission.
Chakhachiro ZI; Saliba RM; Okoroji GJ; Korbling M; Alousi AM; Betul O; Anderlini P; Ciurea SO; Popat U; Champlin R; Samuels BI; Medeiros LJ; Bueso-Ramos C; Khouri IF
Cancer; 2013 Sep; 119(18):3318-25. PubMed ID: 23775587
[TBL] [Abstract][Full Text] [Related]
11. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.
Martin P; Chadburn A; Christos P; Furman R; Ruan J; Joyce MA; Fusco E; Glynn P; Elstrom R; Niesvizky R; Feldman EJ; Shore TB; Schuster MW; Ely S; Knowles DM; Chen-Kiang S; Coleman M; Leonard JP
Ann Oncol; 2008 Jul; 19(7):1327-1330. PubMed ID: 18349031
[TBL] [Abstract][Full Text] [Related]
12. 90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?
Mondello P; Steiner N; Willenbacher W; Arrigo C; Cuzzocrea S; Pitini V; Mian M
Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):82-8. PubMed ID: 26702476
[TBL] [Abstract][Full Text] [Related]
13. R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma.
Frosch Z; Luskin MR; Landsburg DJ; Schuster SJ; Svoboda J; Loren AW; Porter DL; Stadtmauer EA; Nasta SD
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):92-7. PubMed ID: 25174772
[TBL] [Abstract][Full Text] [Related]
14. Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma.
Tam CS; Khouri IF
Leuk Lymphoma; 2009 Aug; 50(8):1239-48. PubMed ID: 19562639
[TBL] [Abstract][Full Text] [Related]
15. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Qiao W; Zhao J; Wang C; Wang T; Xing Y
Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
[TBL] [Abstract][Full Text] [Related]
17. R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.
Ogura M; Yamamoto K; Morishima Y; Wakabayashi M; Tobinai K; Ando K; Uike N; Kurosawa M; Gomyo H; Taniwaki M; Nosaka K; Tsukamoto N; Shimoyama T; Fukuhara N; Yakushijin Y; Ohnishi K; Miyazaki K; Sawada K; Takayama N; Hanamura I; Nagai H; Kobayashi H; Usuki K; Kobayashi N; Ohyashiki K; Utsumi T; Kumagai K; Maruyama D; Ohmachi K; Matsuno Y; Nakamura S; Hotta T; Tsukasaki K;
Cancer Sci; 2018 Sep; 109(9):2830-2840. PubMed ID: 29957865
[TBL] [Abstract][Full Text] [Related]
18. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients.
Dreger P; Martin S; Kuse R; Sonnen R; Glass B; Kröger N; Parwaresch R; Kneba M; Schmitz N; Haas R
Hematol J; 2000; 1(2):87-94. PubMed ID: 11920175
[TBL] [Abstract][Full Text] [Related]
19. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
[TBL] [Abstract][Full Text] [Related]
20. Rituximab based therapy followed by autologous stem cell transplantation leads to superior outcome and high rates of PCR negativity in patients with indolent B-cell lymphoproliferative disorders.
Cerny J; Trneny M; Slavickova A; Pytlik R; Salkova J; Valkova V; Liu Q; Houghton J; Klener P
Hematology; 2009 Aug; 14(4):187-97. PubMed ID: 19635181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
